Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Randomized, Multicenter, Vehicle-Controlled, Parallel Group Study to Determine the Efficacy and Safety of 188-0551 in Subjects With Plaque Psoriasis Receiving Up To Four Weeks of Twice-Daily Treatment

NCT03065556 is registered in ClinicalTrials.gov with Therapeutics, Inc. as lead sponsor.

NCT NCT03065556
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03065556 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Randomized, Multicenter, Vehicle-Controlled, Parallel Group Study to Determine the Efficacy and Safety of 188-0551 in Subjects With Plaque Psoriasis Receiving Up To Four Weeks of Twice-Daily Treatment
Lead sponsor
Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
January 26, 2017
Completion date
December 6, 2017
Enrollment
89 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

plaque psoriasis